Advanced in IgG4-Related Disease

Georg A. Schett

Erlangen, BY, DE 
Advanced in IgG4-Related Disease
Erlangen, BY, DE 
OverviewLocationsClinical Research

Overview

Georg Schett practices in Erlangen, Germany. Mr. Schett is rated as an Advanced expert by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis (RA), Oophorectomy, and Lithotripsy.

His clinical research consists of co-authoring 924 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of IgG4-Related Disease.

Gender
Male

Locations

Erlangen, BY, Germany
Other Locations
Alexander, NW, Germany
Bayern, BY, Germany
Nuernberg, BY, Germany
Charité Universitätsmedizin Berlin
Berlin, BE, Germany
Wuerzburg, BY, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Dose Regimens of CC-10004 in Subjects With Active Psoriatic Arthritis
A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Dose Regimens of CC-10004 in Subjects With Active Psoriatic Arthritis
Enrollment Status: Completed
Publish Date: June 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain. A Multi-center, Randomized Double-blind Controlled Study Prediction of Response to Certolizumab-Pegol in RA (PreCePRA)
Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain. A Multi-center, Randomized Double-blind Controlled Study Prediction of Response to Certolizumab-Pegol in RA (PreCePRA)
Enrollment Status: Completed
Publish Date: March 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

924 Total Publications

BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease.
BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease.
Journal: The New England journal of medicine
Published: October 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schett's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 13 Distinguished Conditions
View All 12 Advanced Conditions
View All 96 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile